, Volume 46, Issue 2, pp 137–147 | Cite as

Different effects of γ-linolenic acid (GLA) supplementation on plasma and red blood cell phospholipid fatty acid composition and calcium oxalate kidney stone risk factors in healthy subjects from two race groups with different risk profiles pose questions about the GLA-arachidonic acid-oxaluria metabolic pathway: pilot study

  • Allen L. Rodgers
  • Dalielah Jappie-Mahomed
  • Paul J. van Jaarsveld
Original Paper


Fatty acid (FA) composition of phospholipids in plasma and red blood cells (RBC) can influence calciuria, oxaluria and renal stone formation. In this regard, the ratio of arachidonic acid (AA) and its precursor linoleic acid (LA) appears to be important. Administration of γ-linolenic acid (GLA) has been shown to increase the concentration of dihomo-gamma linoleic acid (DGLA) relative to AA indicating that it may attenuate biosynthesis of the latter. Such effects have not been investigated in race groups having difference stone occurrence rates. Black (B) and white (W) healthy males ingested capsules containing linoleic acid (LA) and GLA, for 30 days. Plasma and RBC total phospholipid (TPL) FA profiles, serum and 24 h urine biomarkers of hypercalciuria and urinary stone risk factors were determined on days 0 and 30. Data were tested for statistical significance using GraphPadInstat version 3.02. Concentration and percentage content of DGLA in plasma TPL increased in W but not in B. Arachidonic acid (AA) did not change in either group. There was no change in calcium excretion in either group but oxalate and citrate excretion increased in W. We suggest that elongation of GLA to DGLA may occur more rapidly than desaturation of DGLA to AA in W and that depressed activity of the enzyme elongase may occur in B. Calciuric and citraturic effects may be dependent on the quantity of LA or on the mass ratio of LA/GLA in the FA supplement. Questions about the mooted DGLA–AA–oxaluria pathway arise. We speculate that there exists a potential for using GLA as a conservative treatment for hypocitraturia. The observation of different responses in B and W indicates that such differences may play a role in stone formation and prevention.


Phospholipid fatty acid composition n-6 Fatty acid supplementation Kidney stone risk factors Different race groups 



The financial support of the South African Medical Research Council, the South African National Research Foundation and the University of Cape Town is gratefully acknowledged. The authors would like to extend their appreciation to Johanna van Wyk of the NCDRU of the SAMRC for her invaluable laboratory assistance analyzing plasma and RBC total phospholipid fatty acids.

Compliance with ethical standards

Conflict of interest

The authors declare that there are no conflicts of interest.

Ethical approval

The study was approved by the Human Research Ethics Committee of the University of Cape Town (HRE REF: 366/2011) and was performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments.

Informed consent

All participants gave their informed consent before their inclusion in the study.


  1. 1.
    Masai M, Ito H, Kotake T (1995) Effect of dietary intake on urinary oxalate excretion in calcium renal stone formers. Br J Urol 76(6):692–696CrossRefPubMedGoogle Scholar
  2. 2.
    Al Zahrani H, Norman RW, Thompson C, Weerasinghe S (2000) The dietary habits of idiopathic calcium stone-formers and normal control subjects. BJU Int 85(6):616–620CrossRefPubMedGoogle Scholar
  3. 3.
    Naya Y, Ito H, Masai M, Yamaguchi K (2000) Effect of dietary intake on urinary oxalate excretion in calcium oxalate stone formers in their forties. Eur Urol 37(2):140–144CrossRefPubMedGoogle Scholar
  4. 4.
    Baggio B, Gambaro G, Zambon S, Marchini F, Bassi A, Manzato E (1996) Anomalous phospholipid n-6 polyunsaturated fatty acid composition in idiopathic calcium nephrolithiasis. J Am Soc Nephrol 7(4):613–620PubMedGoogle Scholar
  5. 5.
    Baggio B, Budakovic A, Nassuato MA, Vezzoli G, Manzato E, Luisetto G, Zaninotto M (2000) Plasma phospholipid arachidonic acid content and calcium metabolism in idiopathic calcium nephroloithiasis. Kidney Int 58:1278–1284CrossRefPubMedGoogle Scholar
  6. 6.
    IUPAC-IUB Commission on Biochemical Nomenclature (CBN) (1978) The nomenclature of lipids (Recommendations 1976). Biochem J 171:21–35CrossRefGoogle Scholar
  7. 7.
    Fan YY, Chapkin RS (1998) Importance of dietary γ-linolenic acid in human health and nutrition. J Nutr 128:1411–1414CrossRefPubMedGoogle Scholar
  8. 8.
    Hornych A, Oravec S, Girault F, Forette B, Horrobin DF (2002) The effect of gamma-linolenic acid on plasma and membrane lipids and renal prostaglandin synthesis in older subjects. Ratisl Lek Listy 103(3):101–107Google Scholar
  9. 9.
    Poulsen RC, Moughan PJ, Kruger MC (2007) Long-chain polyunsaturated fatty acids and the regulation of bone metabolism. Exp Biol Med 232(10):1275–1288CrossRefGoogle Scholar
  10. 10.
    Rodgers A, Lewandowski S, Allie-Hamdulay S, Pinnock D, Baretta G, Gambaro G (2009) Evening primrose oil supplementation increases citraturia and decreases other urinary risk factors for calcium oxalate urolithiasis. J Urol 182(6):2957–2963CrossRefPubMedGoogle Scholar
  11. 11.
    Calder PC (2007) Dietary arachidonic acid: harmful or helpful? BrJ Nutr 98(3):451–453CrossRefGoogle Scholar
  12. 12.
    Naya Y, Ito H, Masai M, Yamaguchi K (2002) Association of dietary fatty acids with urinary oxalate excretion in calcium oxalate stone-formers in their fourth decade. BJU Int 89(9):842–846CrossRefPubMedGoogle Scholar
  13. 13.
    Henri’qeuz-la Roche C, Rodri’guez-Iturbe B, Parra G (1992) Increased urinary excretion of prostaglandin E2 in patients with idiopathic hypercalciuria is a primary phenomenon. Clin Sci 83(1):75–80CrossRefGoogle Scholar
  14. 14.
    Baggio B, Gambaro G (1999) Abnormal arachidonic acid content of membrane phospholipids—the unifying hypothesis for the genesis of hypercalciuria and hyperoxaluria in idiopathic calcium nephrolithiasis. Nephrol Dial Transplant 14(3):553–555CrossRefPubMedGoogle Scholar
  15. 15.
    Hasanoğlu A, Ercan ZS, Buyan N, Memioğlu N, Hasanoğlu E (1997) Parathormone, 1,25 dihydroxyvitamin D and prostaglandin E2 correlation in children with idiopathic hypercalciuria. Prostaglandins Leukot Essent Fatty Acids 56(3):235–237CrossRefPubMedGoogle Scholar
  16. 16.
    Jonassen JA, Cao LC, Honeyman T, Scheid CR (2003) Mechanisms mediating oxalate-induced alterations in renal cell functions. Crit Rev Eukaryot Gene Expr 13(1):55–72CrossRefPubMedGoogle Scholar
  17. 17.
    Baggio B, Gambaro G, Marchini Cicerello E, Borsatti A (1984) Raised transmembrane oxalate flux in red blood cells in idiopathic calcium oxalate nephrolithiasis. Lancet 324(8393):12–13CrossRefGoogle Scholar
  18. 18.
    Baggio B, Plebani M, Gambaro G (1998) Pathogenesis of idiopathic calcium nephrolithiasis: update 1997. Crit Rev Clin Lab Sci 35(2):153–187CrossRefPubMedGoogle Scholar
  19. 19.
    Johnson MM, Swan DD, Surette ME, Stegner J, Chilton T, Fonteh AN, Chilton FH (1997) Dietary supplementation with γ-linolenic acid alters fatty acid content and eicosanoid production in healthy humans. Am Soc Nutr Sci 127(8):1435–1444Google Scholar
  20. 20.
    Modlin M (1967) The aetiology of renal stone: a new concept arising from studies on a stone-free population. Ann R Coll Surg Engl 40:155–178PubMedPubMedCentralGoogle Scholar
  21. 21.
    Whalley NA, Moraes MF, Shar TG, Pretorius SS, Meyers AM (1998) Lithogenic risk factors in the urine of black and white controls. Br J Urol 82(6):785–790CrossRefPubMedGoogle Scholar
  22. 22.
    Phinney S (1994) Potential risk of prolonged gamma-linolenic acid use. Ann Intern Med 120(8):692CrossRefPubMedGoogle Scholar
  23. 23.
    Andreassi M, Forleo P, Di Lorio A, Masci S, Abate G, Amerio P (1997) Efficacy of gamma-linolenic acid in the treatment of patients with atopic dermatitis. J Int Med Res 25(5):266–274CrossRefPubMedGoogle Scholar
  24. 24.
    Bamford JT, Ray S, Musekiwa A, van Gool C, Humphreys R, Ernst E (2013) Oral evening primrose oil and borage oil for eczema. Cochrane Database Syst Rev 4:1–84Google Scholar
  25. 25.
    Folch J, Lees M, Sloane Stanley GH (1957) A simple method for the isolation and purification of total lipids from animal tissues. J Biol Chem 226(1):497–509PubMedGoogle Scholar
  26. 26.
    Hon G, Hassan M, van Rensburg SJ, Abel S, Marais DW, van Jaarsveld P, Smuts C, Henning F, Erasmus R, Matsha T (2009) Immune cell membrane fatty acids and inflammatory marker, C-reactive protein, in patients with multiple sclerosis. Br J Nutr 102:1334–1340CrossRefPubMedGoogle Scholar
  27. 27.
    Van Jaarsveld PJ, Smuts CM, Tichelaar HY, Kruger M, Benadé AJ (2000) Effect of palm oil on plasma lipoprotein concentrations and plasma low-density lipoprotein composition in non-human primates. Int J Food Sci Nutr 51(Suppl):S21–S30CrossRefPubMedGoogle Scholar
  28. 28.
    Allie-Hamdulay S, Rodgers A (2005) Prophylactic and therapeutic properties of a sodium citrate preparation in the management of calcium oxalate urolthiasis: randomized, placebo-controlled trial. Urol Res 33:116–124CrossRefPubMedGoogle Scholar
  29. 29.
    Tiselius HG (1982) An improved method for the routine biochemical evaluation of patients with recurrent calcium oxalate stone disease. Clin Chim Acta 122:409–418CrossRefPubMedGoogle Scholar
  30. 30.
    Werness PG, Brown CM, Smith LH, Finlayson B (1985) Equil 2: a basic computer program for the calculation of urinary saturation. J Urol 134:1242–1244CrossRefPubMedGoogle Scholar
  31. 31.
    Ryall RL, Hibberd CM, Marshall VR (1985) A method for studying inhibitory activity in whole urine. Urol Res 13(6):285–289CrossRefPubMedGoogle Scholar
  32. 32.
    Theka T, Rodgers A, Lewandowski S, Webber D, Allie-Hamdulay S (2012) Effects of vitamin E ingestion on plasma and urinary risk factors for calcium oxalate urolithiasis in two population groups having different stone-risk profiles: evidence of different physiological handling mechanisms. Urol Res 40(2):113–120CrossRefPubMedGoogle Scholar
  33. 33.
    Rodgers A, Lewandowski S (2002) Effects of 5 different diets on urinary risk factors for calcium oxalate kidney stone formation: evidence of different renal handling mechanisms in different race groups. J Urol 168:931–936CrossRefPubMedGoogle Scholar
  34. 34.
    Kavanagh JP (2006) Supersaturation and renal precipitation: the key to stone formation? Urol Res 34(2):81–85CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany 2017

Authors and Affiliations

  • Allen L. Rodgers
    • 1
  • Dalielah Jappie-Mahomed
    • 1
  • Paul J. van Jaarsveld
    • 2
  1. 1.Department of ChemistryUniversity of Cape TownCape TownSouth Africa
  2. 2.Non-Communicable Diseases Research Unit (NCDRU)South African Medical Research CouncilCape TownSouth Africa

Personalised recommendations